GCP
ABCL icon

GSA Capital Partners’s AbCellera Biologics ABCL Stock Holding History

GSA Capital Partners’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.66M Buy
+211,370
New +$1.03M 0.1% 240
2025
Q4 		– Sell
-212,518
Closed -$1.07M – 1620
2025
Q3 		$1.07M Sell
212,518
-26,021
-11% -$115K 0.09% 358
2025
Q2 		$818K Sell
238,539
-28,356
-11% -$70.6K 0.06% 584
2025
Q1 		$595K Sell
266,895
-322,318
-55% -$924K 0.05% 675
2024
Q4 		$1.73M Buy
589,213
+347,347
+144% +$967K 0.13% 128
2024
Q3 		$629K Buy
241,866
+219,703
+991% +$609K 0.05% 762
2024
Q2 		$66K Sell
22,163
-63,957
-74% -$242K ﹤0.01% 1554
2024
Q1 		$390K Sell
86,120
-264,550
-75% -$1.35M 0.03% 1061
2023
Q4 		$2M Buy
350,670
+204,480
+140% +$948K 0.17% 117
2023
Q3 		$672K Buy
146,190
+135,504
+1,268% +$824K 0.06% 615
2023
Q2 		$69K Buy
+10,686
New +$72.9K 0.01% 1403
2023
Q1 		– Sell
-111,894
Closed -$1.13M – 1431
2022
Q4 		$1.13M Buy
+111,894
New +$1.29M 0.14% 157
2022
Q3 		– Sell
-68,466
Closed -$729K – 1463
2022
Q2 		$729K Buy
68,466
+51,478
+303% +$436K 0.11% 283
2022
Q1 		$166K Buy
+16,988
New +$161K 0.02% 1215

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

GSA Capital Partners's ABCL Position: Q2 2026 in Review

GSA Capital Partners opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 211,370 shares worth $1.66M. The stake represents 0.1% of the portfolio and ranks #240 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in ABCL as recently as Q3 2025.

GSA Capital Partners first reported a position in ABCL in Q1 2022 and has held it in 14 quarters since. The position peaked at $2M in Q4 2023. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • GSA Capital Partners held 211,370 shares of AbCellera Biologics worth $1.66M as of Q2 2026.
  • AbCellera Biologics was a new GSA Capital Partners position in Q2 2026.
  • AbCellera Biologics made up 0.1% of GSA Capital Partners's portfolio in Q2 2026, its #240 holding.
  • GSA Capital Partners first reported a position in AbCellera Biologics in Q1 2022 and has held it in 14 quarters since.
  • GSA Capital Partners's AbCellera Biologics position peaked at $2M in Q4 2023.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.